InSilico (03696.HK): Partnering with Servier on an $888 Million AI-Driven Anti-Tumor Innovative Drug Initiative
On January 5, 2026, InSilico Medicine (stock code: 3696) issued a voluntary announcement, stating that it has entered into a multi-year anti-tumor drug research and development cooperation with Servier, a global independent pharmaceutical company, with a total cooperation value of up to $888 million. This collaboration will focus on challenging targets in the anti-tumor field and jointly develop novel therapeutic drugs by leveraging InSilico Medicine's self-developed artificial intelligence platform Pharma.AI.
According to the terms of the agreement, InSilico Medicine is eligible to receive up to $32 million in upfront payment and near-term development milestone payments, and will take the lead in using its AI technology platform to discover and develop potential drug candidates that meet predetermined standards. Servier will co-share R&D costs and, following the nomination of promising drug candidates, lead subsequent clinical validation, regulatory interactions, and global commercialization processes. Christophe Thurieau, Executive Director of Servier Research Institute, stated that this cooperation demonstrates Servier's confidence in InSilico Medicine's AI platform. Dr. Alex Zhavoronkov, CEO of InSilico Medicine, commented that the collaboration validates the industry's recognition of the company's AI-driven drug R&D capabilities.
As a biotechnology company listed on the Main Board of the Hong Kong Stock Exchange in December 2025, InSilico Medicine has extensive experience in the field of AI-driven drug discovery and development. Its Pharma.AI platform significantly enhances the efficiency of early-stage innovative drug R&D — the average time from project initiation to the nomination of preclinical candidate compounds (PCCs) is only 12-18 months, much shorter than the 4.5 years required for traditional R&D, and each project only needs to synthesize and test about 60-200 molecules. Currently, the company has established a diversified anti-tumor pipeline. Its pan-TEAD inhibitor ISM6331 and MAT2A inhibitor ISM3412 have both launched global multicenter Phase I clinical trials, and four other anti-tumor projects have been fully or partially out-licensed to partners, with relevant Phase I clinical trials progressing steadily.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
